Non-Coding RNA in Microglia Activation and Neuroinflammation in Alzheimer's Disease
Chunxiang He,Ze Li,Miao Yang,Wenjing Yu,Rongsiqing Luo,Jinyong Zhou,Jiawei He,Qi Chen,Zhenyan Song,Shaowu Cheng
DOI: https://doi.org/10.2147/jir.s422114
IF: 4.5
2023-09-21
Journal of Inflammation Research
Abstract:Chunxiang He, 1, 2 Ze Li, 1, 2 Miao Yang, 1, 2 Wenjing Yu, 1, 2 Rongsiqing Luo, 1, 2 Jinyong Zhou, 1, 2 Jiawei He, 1, 2 Qi Chen, 1, 2 Zhenyan Song, 1, 2 Shaowu Cheng 1, 2 1 School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China; 2 Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China Correspondence: Zhenyan Song; Shaowu Cheng, Tel +86 073188458257, Email ; Alzheimer's disease (AD) is a neurodegenerative disorder characterized by complex pathophysiological features. Amyloid plaques resulting from extracellular amyloid deposition and neurofibrillary tangles formed by intracellular hyperphosphorylated tau accumulation serve as primary neuropathological criteria for AD diagnosis. The activation of microglia has been closely associated with these pathological manifestations. Non-coding RNA (ncRNA), a versatile molecule involved in various cellular functions such as genetic information storage and transport, as well as catalysis of biochemical reactions, plays a crucial role in microglial activation. This review aims to investigate the regulatory role of ncRNAs in protein expression by directly targeting genes, proteins, and interactions. Furthermore, it explores the ability of ncRNAs to modulate inflammatory pathways, influence the expression of inflammatory factors, and regulate microglia activation, all of which contribute to neuroinflammation and AD. However, there are still significant controversies surrounding microglial activation and polarization. The categorization into M1 and M2 phenotypes may oversimplify the intricate and multifaceted regulatory processes in microglial response to neuroinflammation. Limited research has been conducted on the role of ncRNAs in regulating microglial activation and inducing distinct polarization states in the context of neuroinflammation. Moreover, the regulatory mechanisms through which ncRNAs govern microglial function continue to be refined. The current understanding of ncRNA regulatory pathways involved in microglial activation remains incomplete and may be influenced by spatial, temporal, and tissue-specific factors. Therefore, further in-depth investigations are warranted. In conclusion, there are ongoing debates and uncertainties regarding the activation and polarization of microglial cells, particularly concerning the categorization into M1 and M2 phenotypes. The study of ncRNA regulation in microglial activation and polarization, as well as its mechanisms, is still in its early stages and requires further investigation. However, this review offers new insights and opportunities for therapeutic approaches in AD. The development of ncRNA-based drugs may hold promise as a new direction in AD treatment. Keywords: Alzheimer's disease, non-coding RNA, neuroinflammation, microglia activation, miRNA, circRNA, lncRNA Alzheimer's disease (AD) is a neurodegenerative disorder characterized by intricate pathophysiological features, affecting 47 million individuals worldwide, with a projected increase to 131 million by 2050. 1 The rising global population of individuals aged 60 and above, accounting for 17.9% of the total population, and a dementia prevalence rate of approximately 4.2% by the end of 2018, 2 pose significant challenges in healthcare and medical services, particularly concerning neurodegenerative diseases such as AD. Cognitive impairment is a pathological condition associated with AD, and it is mainly due to the loss of neurotransmitter acetylcholine (ACh) from the neurons of the central nervous system. The ACh is not only acting as a parasympathetic neurotransmitter but also strengthening the synaptogenesis of active neurons to modulate memory and learning in humans Oxidative stress is a significant contributor to memory impairments, resulting from an imbalance in antioxidant enzymes and excessive production of reactive oxygen species (ROS). An acetylcholinesterase (AChE) inhibitor exhibiting potent antioxidant properties has emerged as a promising therapeutic candidate for the treatment of dementia by enhancing learning and memory. 3,4 The primary neuropathological criteria for AD diagnosis involve the presence of neuritic plaques with extracellular amyloid deposits and neurofibrillary tangles consisting of intracellular hyperphosphorylated tau accumulation. 5 Besides, mitochondrial dy -Abstract Truncated-
immunology